ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.39B |
| Revenue (ttm) | 517.46M |
| Net Income (ttm) | 33.92M |
| Shares Out | 20.98M |
| EPS (ttm) | 1.58 |
| PE Ratio | 41.79 |
| Forward PE | 14.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,502 |
| Open | 67.50 |
| Previous Close | 67.34 |
| Day's Range | 65.43 - 67.97 |
| 52-Week Range | 40.55 - 70.81 |
| Beta | 0.81 |
| Analysts | Strong Buy |
| Price Target | 81.33 (+23.17%) |
| Earnings Date | May 10, 2024 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmac... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price forecast is $81.33, which is an increase of 23.17% from the latest price.
News
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
BAUDETTE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended Mar...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief F...
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial res...
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the refer...
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis
--ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- --ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness--
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium
BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief...
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Ref...
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
BAUDETTE, Minn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and fu...
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief ...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023...
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
BAUDETTE, Minn., Jan. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for ...
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper San...
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3% ; net income available to common shareholders of $9.5 million and d...
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial resu...
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
Cortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
BAUDETTE, Minn., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for ...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for t...
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief ...
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and spec...
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and d...
ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
BAUDETTE, Minn., July 31, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 financial res...
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer...